CA2768711A1 - Gene expression markers for crohn's disease - Google Patents

Gene expression markers for crohn's disease Download PDF

Info

Publication number
CA2768711A1
CA2768711A1 CA2768711A CA2768711A CA2768711A1 CA 2768711 A1 CA2768711 A1 CA 2768711A1 CA 2768711 A CA2768711 A CA 2768711A CA 2768711 A CA2768711 A CA 2768711A CA 2768711 A1 CA2768711 A1 CA 2768711A1
Authority
CA
Canada
Prior art keywords
expression
ibd
genes
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2768711A
Other languages
English (en)
French (fr)
Inventor
Alexander R. Abbas
Hilary Clark
Lauri Diehl
Charles Lees
Colin L. Noble
Jack Satsangi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2768711A1 publication Critical patent/CA2768711A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2768711A 2009-07-20 2010-07-19 Gene expression markers for crohn's disease Abandoned CA2768711A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22704909P 2009-07-20 2009-07-20
US61/227,049 2009-07-20
US30208410P 2010-02-05 2010-02-05
US61/302,084 2010-02-05
PCT/US2010/042487 WO2011011339A1 (en) 2009-07-20 2010-07-19 Gene expression markers for crohn's disease

Publications (1)

Publication Number Publication Date
CA2768711A1 true CA2768711A1 (en) 2011-01-27

Family

ID=42732741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768711A Abandoned CA2768711A1 (en) 2009-07-20 2010-07-19 Gene expression markers for crohn's disease

Country Status (8)

Country Link
US (2) US20110033486A1 (OSRAM)
EP (3) EP2456890A1 (OSRAM)
JP (1) JP2012533322A (OSRAM)
CN (1) CN102639710A (OSRAM)
AU (1) AU2010276392A1 (OSRAM)
CA (1) CA2768711A1 (OSRAM)
SG (1) SG177699A1 (OSRAM)
WO (1) WO2011011339A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
CA2830351A1 (en) 2011-03-25 2012-10-04 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and crohn's disease
WO2014009535A2 (en) * 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
CN105209643A (zh) * 2013-05-17 2015-12-30 豪夫迈·罗氏有限公司 用于诊断和治疗炎性肠病的方法
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
MA39804A (fr) 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
CA2946317A1 (en) * 2014-05-02 2015-11-05 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mruc) requiring colectomy
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN107541790B (zh) * 2016-06-24 2021-07-06 上海交通大学 一种糖基化检测的人凝集素/类人凝集素芯片及制备方法
IT201600090052A1 (it) * 2016-09-06 2018-03-06 Univ Degli Studi Padova Peptide per la diagnosi differenziale della Malattia di Crohn
CN106755293B (zh) * 2016-09-23 2020-09-04 宁波大学 一种与肺癌辅助诊断相关的lncRNA标志物及其应用
EP3522708A4 (en) 2016-10-06 2020-10-07 The Research Foundation For State University Of New York METHODS AND KITS FOR DETECTING A FUSION MESSENGER RNA TRANSCRIPT OR A POLYPEPTIDE CODED BY THE FUSION MESSENGER RNA TRANSCRIPT
JP7437310B2 (ja) * 2018-03-14 2024-02-22 コーニンクレッカ フィリップス エヌ ヴェ Ｒｎａシーケンシングデータの転写発現レベルを解釈するために局所的なユニークな特徴を使用するシステム及び方法
CN108893488A (zh) * 2018-06-19 2018-11-27 刘志强 一种重组质粒、dna疫苗及其制备方法和应用
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN112578122B (zh) * 2019-09-27 2022-08-02 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途
CN116168765B (zh) * 2023-04-25 2023-08-18 山东大学 基于改进strobemer的基因序列生成方法及系统
CN117031004B (zh) * 2023-08-09 2024-10-01 四川省医学科学院·四川省人民医院 一种检测网膜素-1的试剂在制备预测或评估ibs患者生活质量的产品中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0527283B1 (en) 1991-08-12 1997-11-26 Societe Des Produits Nestle S.A. Food composition
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP1534855B1 (en) * 2002-06-25 2010-12-08 Index Diagnostics AB (publ) Method and kit for the diagnosis of ulcerative colitis
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
JP2005102694A (ja) * 2003-09-10 2005-04-21 Japan Science & Technology Agency 末梢血液細胞に示差的に発現されている遺伝子群、およびそれを用いた診断方法とアッセイ方法
EP1844158A4 (en) * 2004-12-06 2010-09-08 Univ Johns Hopkins BIOMARKER FOR INFLAMMATORY ENDURANCE
CA2658563A1 (en) * 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
WO2008079406A2 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
EP2160475A4 (en) * 2007-05-22 2011-02-09 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS
US20090155788A1 (en) * 2007-05-22 2009-06-18 Abbas Alexander R Gene expression markers for inflammatory bowel disease
CA2706729A1 (en) * 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
ES2391792T3 (es) * 2007-12-20 2012-11-29 Index Diagnostics Ab (Publ) Método para la diferenciación de EII y SII y la distinción adicional entre tipos patológicos de EII

Also Published As

Publication number Publication date
WO2011011339A1 (en) 2011-01-27
JP2012533322A (ja) 2012-12-27
EP2456890A1 (en) 2012-05-30
EP2584049A3 (en) 2013-08-28
SG177699A1 (en) 2012-02-28
AU2010276392A2 (en) 2012-03-08
US20110033486A1 (en) 2011-02-10
EP2757160A3 (en) 2014-07-30
EP2584049A2 (en) 2013-04-24
CN102639710A (zh) 2012-08-15
EP2757160A2 (en) 2014-07-23
US20140154275A1 (en) 2014-06-05
AU2010276392A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US20110033486A1 (en) Gene expression markers for crohn's disease
EP2261367A2 (en) Gene expression markers for inflammatory bowel disease
US20090186034A1 (en) Gene expression markers for inflammatory bowel disease
US20140179620A1 (en) Gene expression markers for inflammatory bowel disease
CA2726691C (en) Use of oncogene nrf2 for cancer prognosis
AU2015229270B2 (en) Method for identifying kidney allograft recipients at risk for chronic injury
US20140037618A1 (en) Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
EP1766080A2 (en) Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
US20250101517A1 (en) Identification of unique blood-based gene expression profiles in children with regressive autism spectrum disorder (asd) and ileocolitis
CA2610960A1 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
US20090155788A1 (en) Gene expression markers for inflammatory bowel disease
WO2008079406A2 (en) Gene expression markers for inflammatory bowel disease
JP2008539728A (ja) 膀胱癌バイオマーカーおよびその使用
CN101627128A (zh) 膀胱癌生物标记及其用途
HK1174067A (en) Gene expression markers for crohn's disease
US20180073075A1 (en) Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypes
CN116761896A (zh) 在诊断时确定难以治疗的骨肉瘤患者并通过提供新疗法改善其结果的方法
HK1116662A (en) Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160720